Companies have been actively seeking insurance benefits for their JAK inhibitors in atopic dermatitis.

According to industry sources, Abbvie Korea has also applied for the reimbursement of its ‘Rinvoq (upadacitinib)’ in atopic dermatitis after its indication expansion, following Lilly Korea’s reimbursement application for ‘Olumiant (baricitinib) in May.

Rinvoq had been additionally approved for atopic dermatitis, ankylosing spondylitis, and psoriatic arthritis on October 5th.

Also, with the application for Pfizer Korea’s ‘Cibinqo (abrocitinib)’ in process in addition to the two drugs, whether a viable new treatment option will be introduced to the field of atopic de